SFN treatment was reported to decrease oxidants and to induce Nrf2 expression, antioxidants, and myofibroblast dedifferentiation in normal and IPF fibroblasts (Artaud-Macari et al., 2013). The gene discussed is NFE2L2; the disease is idiopathic pulmonary fibrosis.